Free Trial
NASDAQ:STAB

Statera Biopharma (STAB) Stock Price, News & Analysis

Statera Biopharma logo

About Statera Biopharma Stock (NASDAQ:STAB)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
6 shs
Average Volume
8,392 shs
Market Capitalization
$5 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.

Receive STAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Statera Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STAB Stock News Headlines

Revealed: Steve Jobs' Secret Project Comes to Life on July 21st?
Did Steve Jobs Leave Behind a $25 Trillion Gift for America? In his final years, America's greatest innovator worked on a secretive project beyond Apple's walls— a vision he believed would transform our nation's economy and restore its global leadership. Insiders called it "extraordinary" and "a model for improving America." On July 21st, this hidden legacy could finally be revealed, unlocking what CNBC calls a "$25 trillion opportunity" for generations to come.
Statera BioPharma Inc Ordinary Shares
See More Headlines

STAB Stock Analysis - Frequently Asked Questions

Shares of STAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Statera Biopharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

Today
6/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:STAB
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$5 thousand
Optionable
Not Optionable
Beta
0.05
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:STAB) was last updated on 6/22/2025 by MarketBeat.com Staff
From Our Partners